SMTL ID : 8g63.1

Ralimetinib (LY2228820) in complex with wild type EGFR

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 2.50 Å

Oligo State

monomer

Ligands

1 x YXT: ralimetinib(Non-covalent)

YXT.1: 18 residues within 4Å: Chain A: L.23, V.31, A.48, I.49, K.50, E.67, M.71, L.82, L.93, I.94, T.95, Q.96, L.97, M.98, P.99, G.101, C.102, L.149 11 PLIP interactions: 11 interactions with chain A Hydrophobic interactions: A:V.31, A:A.48, A:K.50, A:L.93, A:T.95, A:T.95, A:L.149, A:L.149 Hydrogen bonds: A:K.50, A:M.98, A:M.98

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Bhattacharjee, D. et al., Inhibition of a lower potency target drives the anticancer activity of a clinical p38 inhibitor. Cell Chem Biol (2023)

Release Date

2023-10-11

Peptides

Epidermal growth factor receptor: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Epidermal growth factor receptor

Related Entries With Identical Sequence